NanoViricides Price Performance
NNVC stock opened at $1.11 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.53 and a quick ratio of 7.53. The firm has a market capitalization of $12.84 million, a P/E ratio of -1.42 and a beta of 0.68. The business’s 50-day moving average is $1.10 and its two-hundred day moving average is $1.22. NanoViricides has a 1 year low of $1.00 and a 1 year high of $2.00.
Institutional Investors Weigh In On NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
- Five stocks we like better than NanoViricides
- What is a SEC Filing?
- 3 attractive stocks that insiders are buying
- How to Invest in Lithium and Lithium Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Best Stocks Under $5.00
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.